Short communication · 29 Dec 2025
Conference abstractPublished 20 Mar 2017
Predictive role of rheumatoid factor and anti-cyclic citrullinated peptide regarding the response to antitumor necrosis factor therapy in rheumatoid arthritis
Carol Davila University of Medicine and Pharmacy, Romania; Victor Babes National Institute, Romania
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: The introduction of biologic therapy has revolutionized the treatment of rheumatoid arthritis (RA). Despite these advances, 20-40% of the patients are declared non-responders to at least one of the therapies. Objectives: Evaluating the predictive role for the response to anti-tumor necrosis factor therapy of rheumatoid factor (RF) isotypes IgM, IgA, anti-cyclic citrullinated peptide (anti-CCP) and the evolution of serum levels of these biomarkers under biologic treatment. We have also assessed the status of this biomarkers and the response to treatment. Methods: Prospective and observational study including 64 patients was followed for 12 months with active RA, uncontrolled by conventional synthetic DMARDs or declared non-responders to one of the biologic DMARDs. Results: Lower baseline titres of RF type IgM (51.36Ã?±95.359 U/ml, p=0.01629), IgA (22.45Ã?±61.256 U/ml, p=0.03336) and anti-CCP (60.82Ã?±26.331 ng/ml, p=0.00011) had predictive value for achieving a good EULAR response at 6 months. Grouping patients in 2 categories (responders/non-responders), we identified significant differences between groups only for anti-CCP and response at 6 months (responders 96.04Ã?±50.355 ng/ml, non-responders 146.16Ã?±41.68 ng/ml, p=0.02834). For the EULAR response at 12 months, lower baseline titres for RF type IgM (92.93Ã?±120.22 U/ml, p=0.01032) and IgA (49.96Ã?±98.08 U/ml, p=0.00247) had predictive value for achieving a good response at 12 months. We didn’t obtain other information grouping patients in 2 categories. Monitoring the evolution of serum levels, we noticed reduction in all three biomarkers tested, statistically significant at 6 and/or 12 months from baseline. Regarding the status (positive/negative) pretreatment and the response to anti-TNF agents, we noticed significant differences regarding status for RF IgA isotype and response to treatment at 12 months (p=0.004). Conclusion: It can be concluded that, beside their diagnostic role, these biomarkers can be used for other purposes in RA.
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Immunome Research.
Commentary · 27 Dec 2025
Stress-Induced Remodeling of Immune Cell Phenotypes
Perspective · 26 Dec 2025
Immune System Dysregulation in Complex Multisystem Disorders
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalImmunome Research
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Gavrila B I”
- BylineArticles whose byline prints “Claudia Ciofu”
- BylineArticles whose byline prints “Carina Mihai”
- BylineArticles whose byline prints “Bojinca M”
- BylineArticles whose byline prints “Gabriela Udrea”
- BylineArticles whose byline prints “Stoica V”
- BylineArticles whose byline prints “Ciotaru D”
- BylineArticles whose byline prints “Mihaela Surcel”
